PCL, Inc. (KOSDAQ: 241820)

Market Cap	29.17B
Revenue (ttm)	8.49B
Net Income (ttm)	-13.28B
Shares Out	59.17M
EPS (ttm)	-186.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	398,668
Average Volume	1,112,332
Open	488.00
Previous Close	486.00
Day's Range	487.00 - 513.00
52-Week Range	486.00 - 2,255.00
Beta	0.14
RSI	31.08
Earnings Date	Mar 21, 2025

About PCL, Inc.

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 241820

Financial Performance

In 2023, PCL, Inc.'s revenue was 8.43 billion, a decrease of -77.35% compared to the previous year's 37.22 billion. Losses were -20.32 billion, 405.7% more than in 2022.